+

WO2003066647A3 - Synthese de molecules de type inositolphosphate glycanne: traitement des troubles de la proliferation cellulaire et de desordres metaboliques caracterises par une resistance a l'insuline - Google Patents

Synthese de molecules de type inositolphosphate glycanne: traitement des troubles de la proliferation cellulaire et de desordres metaboliques caracterises par une resistance a l'insuline Download PDF

Info

Publication number
WO2003066647A3
WO2003066647A3 PCT/FR2003/000345 FR0300345W WO03066647A3 WO 2003066647 A3 WO2003066647 A3 WO 2003066647A3 FR 0300345 W FR0300345 W FR 0300345W WO 03066647 A3 WO03066647 A3 WO 03066647A3
Authority
WO
WIPO (PCT)
Prior art keywords
inositolphosphate
synthesis
treatment
cell proliferation
insulin resistance
Prior art date
Application number
PCT/FR2003/000345
Other languages
English (en)
Other versions
WO2003066647A2 (fr
Inventor
Yves Jean Marcel Chapleur
Patrick Didier Bogdanowicz
Francoise Chretien
Jean-Pierre Antoine Pujol
Original Assignee
Cnrs Ct Nat De Rech Scient
Yves Jean Marcel Chapleur
Patrick Didier Bogdanowicz
Francoise Chretien
Jean-Pierre Antoine Pujol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cnrs Ct Nat De Rech Scient, Yves Jean Marcel Chapleur, Patrick Didier Bogdanowicz, Francoise Chretien, Jean-Pierre Antoine Pujol filed Critical Cnrs Ct Nat De Rech Scient
Priority to AU2003226862A priority Critical patent/AU2003226862A1/en
Publication of WO2003066647A2 publication Critical patent/WO2003066647A2/fr
Publication of WO2003066647A3 publication Critical patent/WO2003066647A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composé de formule A dans laquelle: R1 est choisi dans le groupe constitué par OH, un oligosaccharide, un polysaccharide, et R2=R3=0H; ou au moins un des groupes R1, R2, R3 est un groupe capable de modifier la lipophilie du composé A, l'autre ou les deux autres de ces trois groupes étant OH, et; R4 est choisi dans le groupe constitué par OH, NH2 et un groupe capable de modifier la lipophilie du composé A, et R6 est H ou CH20H, et X est choisi parmi O, NH, S, CH2, et R5 est choisi parmi OH, un oligosaccharide, un polysaccharide et un groupe capable de modifier la biodisponibilité du composé A, et ses sels pharmaceutiquement acceptables.
PCT/FR2003/000345 2002-02-05 2003-02-05 Synthese de molecules de type inositolphosphate glycanne: traitement des troubles de la proliferation cellulaire et de desordres metaboliques caracterises par une resistance a l'insuline WO2003066647A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003226862A AU2003226862A1 (en) 2002-02-05 2003-02-05 Synthesis of inositolphosphate glycan molecules: treatment of cell proliferation disorders and metabolic disorders characterized by insulin resistance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0201327A FR2835527B1 (fr) 2002-02-05 2002-02-05 Synthese de molecules de type inositolphosphate glycanne: traitement des troubles de la proliferation cellulaire et des desordres metaboliques caracterises par une resistance a l'insuline
FR02/01327 2002-02-05

Publications (2)

Publication Number Publication Date
WO2003066647A2 WO2003066647A2 (fr) 2003-08-14
WO2003066647A3 true WO2003066647A3 (fr) 2004-03-25

Family

ID=27619882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/000345 WO2003066647A2 (fr) 2002-02-05 2003-02-05 Synthese de molecules de type inositolphosphate glycanne: traitement des troubles de la proliferation cellulaire et de desordres metaboliques caracterises par une resistance a l'insuline

Country Status (3)

Country Link
AU (1) AU2003226862A1 (fr)
FR (1) FR2835527B1 (fr)
WO (1) WO2003066647A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100197625A1 (en) * 2006-12-21 2010-08-05 D Alarcao Marc Synthetic lipophilic inositol glycans for treatment of cancer and glucose-metabolism disorders
CA3085356A1 (fr) 2017-12-29 2019-07-04 Glycomimetics, Inc. Inhibiteurs heterobifonctionnels de e-selectine et de galectine -3
EP3902797A1 (fr) 2018-12-27 2021-11-03 GlycoMimetics, Inc. C-glycosides inhibiteurs de galectine-3

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006421A1 (fr) * 1997-07-29 1999-02-11 The University Of Virginia Patent Foundation Substances insulinomimetiques de synthese
WO1999038516A1 (fr) * 1998-01-29 1999-08-05 Rademacher Group Limited Proprietes neurotrophiques des ipg and analogues d'ipg

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006421A1 (fr) * 1997-07-29 1999-02-11 The University Of Virginia Patent Foundation Substances insulinomimetiques de synthese
WO1999038516A1 (fr) * 1998-01-29 1999-08-05 Rademacher Group Limited Proprietes neurotrophiques des ipg and analogues d'ipg

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZAPATA A ET AL: "Synthesis and investigation of the possible insulin-like activity of 1d-4-O- and 1d-6-O-(2-amino-2-deoxy-alpha-d-glucopyranosyl)-myo-inos itol 1-phosphate and 1d-6-O-(2-amino-2-deoxy-alpha-d-glucopyranosyl)- myo-inositol 1,2-(cyclic phosphate)", CARBOHYDRATE RESEARCH, ELSEVIER SCIENTIFIC PUBLISHING COMPANY. AMSTERDAM, NL, vol. 264, no. 1, 1 November 1994 (1994-11-01), pages 21 - 31, XP004065535, ISSN: 0008-6215 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Also Published As

Publication number Publication date
FR2835527A1 (fr) 2003-08-08
AU2003226862A1 (en) 2003-09-02
WO2003066647A2 (fr) 2003-08-14
AU2003226862A8 (en) 2003-09-02
FR2835527B1 (fr) 2004-03-12

Similar Documents

Publication Publication Date Title
CA2474578A1 (fr) Nouveaux derives de pyridine et de pyrimidine
MY137039A (en) Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof
EP1382603A4 (fr) Compose azote a anneaux condenses possedant un groupe pyrazolyle et servant de substituant, et composition medicale le comprenant
MX2008000255A (es) Activadores de urea glucocinasa.
GB0021831D0 (en) Chemical compounds
WO2005060711A3 (fr) Procedes de traitement d'un trouble
IL164007A (en) Compounds and pharmaceutical compositions inhibiting histone deacetylase, their use and process for their manufacture
WO2008108380A3 (fr) Composés de pyrrole
NZ514477A (en) Adamantane derivatives
MX2009004096A (es) Metabolitos de talarozol.
MY145408A (en) Dihydropyrazolopyrimidinone derivatives
WO2005044192A3 (fr) Composes triazole et utilisations associees
UA83233C2 (ru) Замещенный 2-аминотетралин для лечения депрессии
TW200732332A (en) Oxazole compound and pharmaceutical composition
HK1094425A1 (en) Substituted 2-aminotetralines for the preventive treatment of parkinson's disease
WO2006099943A8 (fr) 8-n-benzimidazoles a substitution amide, leur procede de production, et leur utilisation en tant que medicaments
WO2003037864A1 (fr) Compose indolique, et utilisation a des fins therapeutiques
AP2002002578A0 (en) Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses.
WO2005026112A3 (fr) Procedes de traitement de troubles
WO2005097788A3 (fr) Sulfonamides et utilisations de ceux-ci
WO2007099548A3 (fr) Nouvelles 11 beta - hydroxyandrosta-4-ene-3-ones
WO2004043956A8 (fr) Composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002092072A3 (fr) Medicaments contre la maladie d'alzheimer
WO2006103545A8 (fr) Composes de 4-piperazinylthieno [2,3-d] pyrimidine en tant qu'inhibiteurs de l’agregation plaquettaire
MY138547A (en) N-substituted nonaryl-heterocyclic nmda/nr2b antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载